Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF) received a notice of allowance for its Australian patent application covering the composition of matter for its therapeutic candidate MB-204. The Australian patent application 2021235803 was accepted on May 7, 2026, with the patent expected to be granted shortly after August 28, 2026.

MB-204 is a fluorinated analogue of istradefylline, an approved adenosine A2a receptor antagonist used for treating Parkinson's Disease. The company states that MB-204 has demonstrated superior pharmacokinetics and completed preclinical toxicology testing, showing efficacy in depression and multiple autism models including Rett Syndrome.

"We are continuing to extend our composition of matter patent protection of MB-204 to all major markets," said Marvel CEO Rod Matheson. "We have also recently filed for patents on a novel liquid-based formulation of MB-204 which should help lengthen the lifetime of our patent estate."

The Calgary-based biotechnology company has previously secured U.S. and Japanese composition-of-matter patents for MB-204 in 2026. Marvel also selected Novotech as its contract research organization for a planned Phase I clinical trial and secured non-dilutive funding support from Alberta Innovates.

Marvel is developing treatments for neurological diseases and neurodevelopmental disorders, with MB-204 currently being tested in Fragile X models. The company reports that approximately 1 in 36 children at age 8 have been diagnosed with autism spectrum disorder.